Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, Möller C, Lannfelt L. · 2023
Read Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. by Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, Möller C, Lannfelt L. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10119362.txt.
Introduction
Söderberg and colleagues compare how three Alzheimer's antibody drugs bind to different forms of amyloid-beta, in a 2023 study. The drugs are lecanemab, aducanumab, and gantenerumab. Amyloid-beta comes in several forms, from single molecules to clumps and plaques, and the loose clumps seem most harmful to brain cells.
The team measured each drug's grip on each form of the protein. The binding patterns differ in ways that may explain why trial results and side effects differed too. The study helps clarify how these much-debated drugs actually work. It also informs the design of future trials.
Catalog record
| CREATOR | Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, Möller C, Lannfelt L. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease By Linda Söderberg, Malin Johannesson, Patrik Nygren, Hanna Laudon, Fredrik Eriksson, Gunilla Osswald, Christer Möller, Lars Lannfelt Published in: Neurotherapeutics DOI: 10.1007/s13311-022-01308-6 ABSTRACT Abstract Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of Alzheimer’s disease (AD). Aβ exists as various species, including monomers, oligomers, protofibrils, and insoluble fibrils in plaques. Oligomers and protofibrils have been shown to be toxic, and removal of these aggregates might represent an effective treatment for AD. We have characterized the binding properties of lecanemab, aducanumab, and gantenerumab to different Aβ species with inhibition ELISA, immunodepletion, and surface plasmon resonance. All three antibodies bound monomers with low affinity. However, lecanemab and aducanumab had very weak binding to monomers, and gantenerumab somewhat stronger binding. Lecanemab was distinctive as it had tenfold stronger binding to protofibrils compared to fibrils. Aducanumab and gantenerumab preferred binding to fibrils over protofibrils. Our results show different binding profiles of lecanemab, aducanumab, and gantenerumab that may explain clinical results observed for these antibodies regarding both efficacy and side effects. Supplementary Information The online version contains supplementary material available at 10.1007/s13311-022-01308-6. Keywords: Amyloid-beta species, Therapeutic antibodies, Lecanemab, Aducanumab, Gantenerumab INTRODUCTION According to the amyloid hypothesis, amyloid-beta (Aβ), the main constituent of extracellular plaques found in Alzheimer’s disease (AD) brains [1, 2], initiates the disease process and is therefore an attractive target for therapeutic intervention [3]. Aβ exists as various species, including monomers, soluble aggregates of varying size (e.g., oligomers and protofibrils), and insoluble fibrils in plaques [4, 5]. Studies of Aβ with the Arctic mutation showed that the peptide had an increased propensity to form soluble Aβ protofibrils and data indicated that these protofibrils were neurotoxic and contributed to the disease process [6–8]. Furthermore, it has been shown that soluble Aβ aggregates are more neurotoxic than monomers and insoluble fibrils [9, 10]. It could therefore be hypothesized that removal of these soluble Aβ aggregates would represent an effective approach for the treatment of AD [11, 12]. Immunotherapy has emerged as a promising treatment option for AD, although many challenges remain. Several monoclonal antibodies have entered clinical trials with varying degree of success. The clinical program of bapineuzumab [13], a monoclonal antibody with a high affinity for all forms of Aβ, was terminated since the desired clinical effect was not achieved [14]. Solanezumab was developed to target the mid-region of soluble, monomeric Aβ. In phase 3 studies, solanezumab failed to meet primary clinical endpoints [15]. Crenezumab, a monoclonal IgG4 antibody, which binds both monomeric and oligomeric forms of Aβ, was investigated in a phase 3 trial with similar results [16, 17]. Results from the clinical trials with solanezumab and crenezumab showed no, or limited, clinical effect signals and limited plaque clearance. There are currently four monoclonal antibodies targeting Aβ in late-phase clinical development, lecanemab, aducanumab, gantenerumab, and donanemab. All four are monoclonal IgG1 antibodies targeting aggregated forms of Aβ. Lecanemab is a humanized version of the murine mAb158 antibody targeting soluble Aβ aggregates (oligomers and protofibrils) with high selectivity [10, 18, 19]. mAb158 was generated at Uppsala University, and lecanemab was further developed by BioArctic and Eisai. Lecanemab showed profound plaque clearance and efficacy signals in a phase 2b clinical study [20]. Aducanumab, developed by Biogen, is a recombinant human antibody that binds to amino acids 3–7 of the Aβ peptide. Development of aducanumab was halted in 2019 after analysis of the data from two phase 3 trials indicated that the primary endpoint would not be met. Further analysis of the data showed profound plaque clearance and an efficacy signal supporting progression of the clinical program, and aducanumab was approved in the USA by FDA in 2021 [21–24]. Gantenerumab was identified from a human combinatorial antibody library and is being developed by Roche. It differs from the other three in that it targets both the N-terminal, 3–11, and mid-regions, 18–27, of the Aβ peptide [25]. Two phase 3 clinical trials with gantenerumab were stopped in 2014 after an interim futility analysis reported no efficacy on primary or secondary endpoints. The antibody has since then reentered clinical development and is currently in two phase 3 trials with readouts expected in the fall of 2022. Data from late phase clinical trials indicates that Aβ immunotherapy can have positive effects. However, amyloid-related imaging abnormalities, mainly with edema (ARIA-E), have been observed. The main risk factors identified for developing ARIA-E have been antibody dose and the presence of the apolipoprotein E4 (ApoE4) allele [26]. The exact mechanism for the occurrence of ARIA-E has not been elucidated, but probable explanations involve direct binding of Aβ antibodies to cerebral amyloid angiopathy (CAA) [27, 28], or accelerated formation of CAA [29]. CAA is a pathology consisting of fibrillar Aβ, mainly Aβ1-40 [30], deposited in the blood vessel walls and is a common occurrence in AD [31, 32]. ARIA-E has been observed with the following frequencies: lecanemab 10% [20, 33], aducanumab 35% [21–24], gantenerumab 30% [23], and donanemab 27% [34]. In the present study, we report on in vitro, side-by-side comparisons of binding characteristics of three of the antibodies in late-phase clinical development, lecanemab, aducanumab, and gantenerumab. Donanemab was excluded since it does not bind N-terminal full-length Aβ, the peptide used in our studies [34, 35]. Binding of the antibodies to Aβ monomers, cross-linked oligomers, small and large protofibrils, and fibrils (Table 1) have been examined using inhibition ELISA, immunodepletion, and surface plasmon resonance (SPR). The data, while corroborating that all three antibodies are highly aggregate selective, show also that there are distinct differences. Aducanumab and gantenerumab demonstrated selectivity towards fibrils over protofibrils, whereas lecanemab showed stronger binding to protofibrils than to fibrils. These data are in line with previous published data on mAb158, the murine precursor of lecanemab [18]. To our knowledge, this is the first study where the binding profiles of the three antibodies have been compared side-by-side. It is possible that the differences seen in the binding profiles of lecanemab, aducanumab, and gantenerumab may explain the variation in efficacy and frequency of ARIA-E observed in the clinical trials. [Table: Size comparison of Aβ species used in this study] MATERIAL AND METHODS Generation of Anti-Aβ Antibodies Based on publicly available sequence information on aducanumab [36] and gantenerumab [37], analogues were recombinantly produced. Gantenerumab was produced transiently in HEK293 cells using the Absolute Antibody HEXpress™ antibody expression platform and proprietary vectors (Absolute Antibody, Oxford, UK). Purification was done by affinity chromatography and size exclusion chromatography (SEC). The final buffer was PBS, pH 7.2 (Gibco, Cat. No. 20012–019). Aducanumab was produced transiently in CHOK1SV GS-KO cells using the single gene GS expression vectors pXC-184 and pXC-17.4 (Lonza Biologics, Cambridge, UK). Purification was done by protein A affinity chromatography and SEC and the final buffer was PBS, pH 7.2. The purity was estimated to be above 98% by SEC and by SDS-PAGE under denaturing conditions. Lecanemab was provided by Eisai Co., Ltd. Preparation of Different Aβ Species Aβ peptides were purchased from Bachem (Bachem, Inc., Switzerland). Lyophilized peptides of Aβ1-40, Aβ1-42, and Aβ1-28 were reconstituted in 10 mM NaOH, 0.005% Tween-20, pH 11 to a concentration of